Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Hiring Stern

<< Previous

Bullboard Posts

Next >>

Comment by Howsitgoing2020on Aug 17, 2020 5:04pm

179 Views

Post# 31419866

RE:RE:RE:Hiring Stern

You're referencing that the trial allowed patients to simultaneously dose with acetaminophen at their own discretion right? Which in turn caused the higher liver enzymes in some. I'm sure big pharma is aware of this and reasonable determine how much Atb-346 vs acetaminophen caused the liver enzyme increase. If Atb-346 was the sole cause, don't you think all patients would have had increased liver enzymes and not just a smaller sample that also took acetaminophen?

<< Previous

Bullboard Posts

Next >>

A junior copper-gold stock trading at a bargain of monumental proportions